Previous 10 | Next 10 |
Point Roberts, WA and Vancouver, BC - May 3, 2021 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com ), a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye - watching stock news, deal tracker and advancemen...
Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence ...
Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company's Progress in the Development of Biopharma Collaborations and Partnerships and Advancing the Company's Strategy to Develop the World's...
Lantern Pharma to Host First Quarter 2021 Operating and Financial Results Conference Call on May 3, 2021 at 4:30 p.m. ET PR Newswire DALLAS , April 26, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN) , a clinical stage biopharmaceutical company usi...
Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget - Preclinical evidence supports the development of LP-184 in non-small cell lung cancers (NSCLC) for patients inel...
Lantern Pharma Inc. is a clinical-stage oncology biotechnology company utilizing AI, machine learning, and genomic data to develop, streamline, rescue, and revitalize small-molecule drugs (oftentimes abandoned or failed) for targeted oncology patients. Lantern's pipeline con...
Lantern Pharma to Participate in the Virtual 20th Annual Needham Healthcare Conference PR Newswire DALLAS , April 6, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN) , a clinical stage biopharmaceutical company using its proprietary RADR ® ...
Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins - Initiates studies in collaboration with pediatric brain cancer expert, Dr. Eric Raabe, M.D., Ph.D - Collaboration will leverage Dr. Raabe's ...
Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021 - Preclinical Work Supports the Development of LP-184 in Prostate Cancer with DNA Damage Repair Aberrations PR Newswire DALLAS , March 23, 2021 /P...
Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties PR Newswire DALLAS , March 17, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using i...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...